AMA Been inundated with many questions recently!

The name change from PCOS to PMOS has generated many questions! Here are the top 10

10 Questions for Dr. Herman Weiss

1. What is PMOS, and is it actually different from PCOS?
   For women who were diagnosed with PCOS years ago, what does this name change really mean?

   Yes — and the distinction matters more than you might think. PMOS stands for Polycystic Metabolic-Ovarian Syndrome. It’s not just a rebranding exercise. It’s a scientific correction that’s been decades overdue. The old name, PCOS — Polycystic Ovary Syndrome — told women this was a problem with their ovaries and their cysts. But here’s the clinical reality: the ovaries are not the source of the problem. They’re a downstream target. The real driver is a complex interplay of insulin resistance, metabolic dysregulation, androgen excess, and chronic low-grade inflammation. The ovaries respond to that environment — they don’t create it. For women who were diagnosed with PCOS years ago, this name change means your diagnosis finally reflects what’s actually happening in your body. It means your weight struggles, your brain fog, your fatigue, your cardiovascular risk — these aren’t side effects. They’re central features of the same underlying condition. It means you weren’t imagining things when “it’s just a hormonal issue” never felt like the whole story. As a physician, I’ve spent 25 years watching women leave appointments feeling blamed and confused. PMOS is the beginning of an honest conversation.
   
   

2. Why did it take medicine so long to rename this condition?
   If so many women felt misunderstood by the term PCOS, what was the delay?

   Medicine moves slowly when money and inertia are aligned. PCOS as a term has been embedded in ICD codes, insurance billing, pharmaceutical trials, research grants, and medical education for over 80 years. Changing a name isn’t just a semantic decision — it requires consensus across specialties, regulatory bodies, and institutions that don’t always communicate well with each other. But I’ll be direct about the other part of the answer: women’s health has historically been underfunded, understudied, and underrepresented in research. Conditions that predominantly affect women — PCOS, endometriosis, fibroids, perimenopause — have been systematically deprioritized in medical literature for generations. That’s not opinion; that’s documented funding disparity. The good news is that the metabolic science has now reached a tipping point. The explosion of research around insulin resistance, the microbiome, mitochondrial function, and the gut-hormone axis has made the old framing impossible to defend. The name PMOS is beginning to appear in the academic literature, and I believe it will become the standard within this decade. For patients who felt dismissed for years? Your frustration was valid. The science caught up to your experience — not the other way around.
   
   

3. Can a woman have PMOS even if her ultrasound shows no ovarian cysts?
   What should women know if they have symptoms like irregular cycles, acne, weight gain, or hair changes, but their doctor says the ultrasound is “normal”?

   Absolutely. And this is one of the most consequential misunderstandings in women’s health today. Under the Rotterdam Criteria — which is still the most widely used diagnostic framework — you only need two of three findings to be diagnosed: irregular cycles, elevated androgens, or polycystic ovarian morphology on ultrasound. That means a “normal” ultrasound does not rule out this condition. Full stop. The name “polycystic” has caused enormous harm here. Women come in with irregular cycles, acne, hirsutism, insulin resistance, and weight gain — textbook PMOS — and they’re told they’re fine because the ultrasound didn’t show the classic “string of pearls.” That’s a diagnostic failure, not a clean bill of health. What I tell women in my practice: if you have two or more of the following — irregular periods, unexplained weight gain especially around the midsection, acne or oily skin that doesn’t respond normally to treatment, excess facial or body hair, hair thinning on the scalp, or a first-degree relative with PCOS or type 2 diabetes — you deserve a full hormonal and metabolic workup. That means fasting insulin, HOMA-IR, total and free testosterone, DHEA-S, SHBG, fasting glucose, HbA1c, and a full lipid panel. Not just an ultrasound. Your symptoms are data. Don’t let a single normal test convince you otherwise
   
   

4. Why does PMOS make weight loss so much harder?
   What is happening hormonally or metabolically that makes the usual advice to “eat less and move more” feel so frustrating?

   Because “eat less and move more” is advice built for a normally functioning metabolic system. PMOS is, at its core, a metabolic condition — and the metabolic machinery is broken in specific, measurable ways. Here’s what’s actually happening. First: insulin resistance. When cells don’t respond properly to insulin, glucose can’t be efficiently cleared from the bloodstream. The pancreas compensates by producing more insulin. Chronically elevated insulin is a powerful fat-storage signal, particularly for visceral adipose tissue. You’re not overeating your way to weight gain — you’re insulin-resistant, and your body is doing exactly what elevated insulin tells it to do. Second: hyperandrogenism. Elevated androgens — testosterone, DHEA-S — shift fat distribution toward the abdomen and interfere with adipose tissue metabolism. They also amplify insulin resistance. It’s a cycle. Third: disrupted hunger signaling. Women with PMOS frequently have leptin resistance and altered ghrelin patterns, which means the hormonal signals that should tell your brain “I’m full” or “I’m not hungry anymore” are misfiring. This is not a willpower problem. This is a signaling problem. Fourth: the gut microbiome. Emerging research — and I find this compelling — shows that dysbiosis, meaning an imbalanced gut microbial community, impairs estrogen metabolism through the estrobolome, drives systemic inflammation, and worsens insulin sensitivity. Your gut is not peripheral to PMOS. It may be central to it. When I hear a woman say she’s eating 1,400 calories, exercising five days a week, and still gaining weight — I don’t question her effort. I look for the metabolic blockade.
   
   

5. Is there one best diet for PMOS, or does that question miss the point?
   How should women think about keto, low GI, Mediterranean, intermittent fasting, and other popular approaches?

   The question doesn’t miss the point — but the framing of “best diet” usually does. Here’s my clinical perspective: the primary therapeutic target in PMOS is insulin resistance. Any dietary approach that consistently lowers fasting insulin, reduces postprandial glucose spikes, and supports a healthy gut microbiome is going to be beneficial. The specific protocol is less important than whether it achieves those metabolic goals and whether the woman can sustain it. With that said: the evidence for low-glycemic and ketogenic approaches is particularly strong in PMOS. Carbohydrate restriction directly reduces the insulin load, which is the most efficient lever we have for reversing insulin resistance. In my clinical experience and in the published literature, women with PMOS who reduce refined carbohydrates — even without aggressive caloric restriction — frequently see improvements in cycle regularity, androgen levels, and body composition within 8 to 12 weeks. The Mediterranean diet shows strong data for cardiovascular risk reduction and anti-inflammatory effects — both highly relevant in PMOS. Intermittent fasting can improve insulin sensitivity and metabolic flexibility, though women need to be thoughtful about how fasting protocols affect cortisol and HPA axis function. What I tell my patients: we need to find your personal metabolic response, not the statistically average one. That’s where tools like continuous glucose monitoring become genuinely useful — not for diabetics, but for metabolically vulnerable women who want to understand how their specific body responds to specific foods. That’s precision nutrition. That’s the future of managing PMOS.
   
   

6. What does PMOS look like after 40?
   For women with regular cycles who suddenly feel anxious, foggy, tired, or different in their bodies, how do PMOS, perimenopause, and ovarian aging overlap?

   This is one of the most underrecognized clinical situations I see, and it’s one I care deeply about. Perimenopause typically begins in a woman’s early-to-mid 40s and is characterized by fluctuating — and eventually declining — estrogen and progesterone. But here’s what’s underappreciated: women with underlying PMOS enter perimenopause with a metabolic system that’s already under strain. The hormonal volatility of perimenopause doesn’t just cause hot flashes and mood changes — it further destabilizes insulin sensitivity, amplifies inflammation, and accelerates the cardiovascular and metabolic risks that PMOS already confers. The symptom overlap is real and clinically challenging. Anxiety, brain fog, fatigue, weight gain around the abdomen, sleep disruption, low libido — these can all be features of PMOS, perimenopause, or both simultaneously. And there’s a third variable: thyroid dysfunction, which is more common in women with PMOS and increases in prevalence in the perimenopausal decade. All three can look nearly identical on a symptom checklist. My approach: any woman over 40 presenting with this symptom constellation needs a comprehensive hormonal panel — FSH, LH, estradiol, progesterone timed to cycle phase if she’s still cycling, testosterone, SHBG, insulin, and thyroid including reverse T3. You need the full picture before you can meaningfully intervene. What I don’t want is for a woman to be told, “You’re just perimenopausal,” when she’s actually experiencing an acceleration of metabolic disease that’s been brewing for years and is now entirely treatable.
   
   

7. What should mothers tell their daughters about PMOS?
   If a younger woman has irregular periods, acne, unwanted hair growth, or unexplained weight changes, when should she push for a deeper evaluation?

   Tell her that her symptoms are real, her body is giving her information, and she deserves a physician who takes that information seriously. PMOS has a strong hereditary component. If a mother has PCOS or PMOS, her daughter has a significantly elevated risk. That means early identification isn’t just possible — it’s a clinical and ethical obligation. The signs to watch for in adolescent and young adult women: periods that are consistently irregular beyond the first two years post-menarche; acne that is persistent, severe, or cystic and doesn’t respond well to standard treatment; hirsutism — unwanted hair growth on the face, chin, chest, or lower abdomen; unexplained weight gain especially in the abdominal area; and skin changes like acanthosis nigricans, the dark, velvety patches in skin folds that signal insulin resistance. The challenge in adolescents is that irregular cycles in the first year or two after first period are developmentally normal. But beyond that window, irregular cycles need investigation — not just a prescription for oral contraceptives. The pill will regulate the cycle, but it doesn’t treat the underlying insulin resistance. I’ve seen women spend their entire 20s on oral contraceptives for “irregular periods” and only discover their PMOS diagnosis at 30 when they’re struggling to conceive. Push for a fasting insulin level. Push for total and free testosterone. Push for a metabolic panel. And if the first physician dismisses the concern, find another physician. A PMOS diagnosis at 17 with proper metabolic intervention is a fundamentally different trajectory than a PMOS diagnosis at 35. The earlier we intervene, the more we can change the long-term story.
   
   

8. Does being on the pill treat PMOS, or can it hide what is really going on?
   Many women were put on birth control as teenagers to “regulate” their cycles. What did that help, and what might it have missed?

   The pill manages symptoms. It does not treat the underlying condition. And for a long time, our field conflated those two things — to the significant detriment of a generation of women. Here’s what oral contraceptives genuinely do in PMOS: they suppress endogenous androgens, which reduces acne and hirsutism. They regulate the withdrawal bleeding that women experience as a “period,” which protects against endometrial hyperplasia from unopposed estrogen. For women who need contraception, they serve a dual purpose. These are real clinical benefits. Here’s what they don’t do: they don’t reverse insulin resistance. They don’t reduce hyperinsulinemia. Some formulations actually worsen insulin sensitivity, depending on the progestin component. They don’t address the gut microbiome. They don’t modify long-term cardiovascular or metabolic risk. And they suppress ovarian function in a way that makes accurate hormonal assessment nearly impossible while on them. The problem I see repeatedly: a 16-year-old comes in with irregular periods and acne. She’s put on the pill. The acne clears. The periods “regulate.” She feels better. No one revisits the underlying diagnosis. She stays on the pill for 10 to 15 years. Then she comes off at 28 or 30 wanting to conceive — and the PMOS, never addressed, has been compounding in the metabolic background the entire time. I want to be clear: I’m not anti-pill. I prescribe it regularly. But I prescribe it as symptom management while we concurrently address the metabolic root. It should be part of a treatment plan, not a substitute for one.
   
   

9. What does an evidence-based PMOS treatment plan look like today?
   From diagnosis forward, what should women expect in terms of testing, lifestyle changes, medications, follow-up, and long-term monitoring?

   A properly constructed PMOS treatment plan is metabolic medicine — not just hormone management. Here’s how I approach it. Diagnosis and baseline: A full metabolic and hormonal panel is non-negotiable. Fasting insulin and glucose with HOMA-IR calculation. Total and free testosterone, DHEA-S, SHBG, LH, FSH. Complete lipid panel with LDL particle size if available. HbA1c. Thyroid panel including TSH and free T3. A pelvic ultrasound for baseline ovarian morphology. And in the right clinical context, a gut microbiome assessment — the data here is growing and I believe this will become standard of care. Lifestyle: This is first-line therapy, not a footnote. A low-glycemic or ketogenic nutritional approach for insulin resistance. Resistance training — not just cardio — because skeletal muscle is the primary site of insulin-mediated glucose disposal and building it is one of the most powerful interventions we have. Sleep hygiene, because sleep deprivation directly worsens insulin sensitivity and elevates cortisol. Stress management, because chronic HPA axis activation drives cortisol-mediated insulin resistance. This isn’t soft medicine — it’s mechanistically grounded intervention. Supplementation with evidence base: Myo-inositol and D-chiro-inositol in a 40:1 ratio — this is the strongest supplement data we have in PMOS, with meaningful effects on insulin sensitivity and ovulatory function. N-acetyl cysteine. Magnesium. Omega-3 fatty acids for anti-inflammatory effect. In selected patients, a targeted probiotic formulation to support the estrobolome. Medications when indicated
   
   

10. When should GLP-1 medications like semaglutide be considered for PMOS?
    Who may be a good candidate, who should avoid them, and what should women understand before asking their doctor?

    GLP-1 receptor agonists represent one of the most significant advances in metabolic medicine of the past decade, and their relevance to PMOS is substantial. But they are powerful tools, and precision matters. Who is a reasonable candidate: Women with PMOS who have documented insulin resistance and a BMI above 27 with metabolic comorbidities — or above 30 without — who have made a sincere effort at lifestyle modification and are not achieving adequate metabolic control. Women with PMOS-related infertility where excess weight is a significant contributing factor may also benefit, though this requires careful coordination with reproductive endocrinology. Women who have prediabetes or early type 2 diabetes in the setting of PMOS are strong candidates. Beyond weight loss — and this is important — GLP-1 agonists directly improve insulin sensitivity, reduce hepatic glucose output, decrease systemic inflammation, and may have beneficial effects on ovarian androgen production. The mechanism isn’t simply caloric restriction. These drugs are working on the same metabolic pathways that are dysregulated in PMOS. Who should be cautious or avoid: Women who are pregnant or planning pregnancy in the near term — current guidance recommends stopping semaglutide at least two months before attempting conception, and there is insufficient safety data in pregnancy. Women with a personal or family history of medullary thyroid carcinoma or MEN2. Women with a history of pancreatitis. Women with significant gastrointestinal conditions. What women should understand before asking their doctor: These medications require a proper clinical evaluation — not a telehealth prescription mill. The side effect profile, particularly nausea and GI symptoms, is real.

Medical Disclaimer

The information provided in this blog post and newsletter is for educational and informational purposes only. It does not constitute medical advice or professional services and should not be used to diagnose or treat any health problem or disease. Always seek the advice of your physician or other qualified health‑care provider regarding a medical condition. Never disregard professional medical advice or delay seeking it because of something you have read here.

Use of this content does not create a doctor–patient relationship. Individual responses to treatments and lifestyle changes can vary, and only your healthcare provider can evaluate your specific circumstances. If you are experiencing a medical emergency, call your local emergency services immediately.